Medtronic Spotlights Endeavor Stent Launch Abroad, ICDs Domestically
This article was originally published in The Gray Sheet
Executive Summary
Medtronic believes it can capture more than 15% of the international drug-eluting stent market within one year of rolling out its Endeavor in 40 countries outside the U.S
You may also be interested in...
Medtronic Presents Durable Endeavor DES Results At ESC Meeting
Medtronic's PMA for the Endeavor ABT-578-eluting stent will include data from over 2,800 patients, including three-year follow-up from the 100-patient ENDEAVOR-I trial
Boston Scientific Holds To Year-Long Guidance Despite Weak Sales In August
Boston Scientific attributes lower than expected stent sales in August to Johnson & Johnson/Cordis' increased stent supply capacity rather than the European launch of Medtronic's Endeavor drug-eluting stent
Medtronic Presents Durable Endeavor DES Results At ESC Meeting
Medtronic's PMA for the Endeavor ABT-578-eluting stent will include data from over 2,800 patients, including three-year follow-up from the 100-patient ENDEAVOR-I trial